Liver cancer: time to evolve trial design after everolimus failure.
作者： Josep M. Llovet
DOI: 10.1038/NRCLINONC.2014.136
关键词:
摘要: Hepatocellular carcinoma is a difficult-to-treat cancer and, after numerous phase III trials assessing kinase inhibitors have failed to meet their end points, sorafenib the only accepted treatment for advanced stages of disease. Now, trial EVOLVE-1 has shown lack benefit everolimus in second-line setting.
nature.com
sci-hub.se 参考文章(11)
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857
Josep M Llovet, Jordi Bruix, Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival Hepatology. ,vol. 37, pp. 429- 442 ,(2003) , 10.1053/JHEP.2003.50047
Augusto Villanueva, Josep M. Llovet, Liver cancer in 2013: Mutational landscape of HCC—the end of the beginning Nature Reviews Clinical Oncology. ,vol. 11, pp. 73- 74 ,(2014) , 10.1038/NRCLINONC.2013.243
Ronald A. DePinho, Paraskevi A. Farazi, Hepatocellular carcinoma pathogenesis: from genes to environment Nature Reviews Cancer. ,vol. 6, pp. 674- 687 ,(2006) , 10.1038/NRC1934
Eunice L. Kwak, Yung-Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai-Hong I. Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella-Garcia, Woo-Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, WeiWei Tan, Leena Gandhi, Mari Mino-Kenudson, Greg C. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate, Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 363, pp. 1693- 1703 ,(2010) , 10.1056/NEJMOA1006448
Josep M. Llovet, Virginia Hernandez-Gea, Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design Clinical Cancer Research. ,vol. 20, pp. 2072- 2079 ,(2014) , 10.1158/1078-0432.CCR-13-0547
Andrew X. Zhu, Masatoshi Kudo, Eric Assenat, Stéphane Cattan, Yoon-Koo Kang, Ho Yeong Lim, Ronnie T. P. Poon, Jean-Frederic Blanc, Arndt Vogel, Chao-Long Chen, Etienne Dorval, Markus Peck-Radosavljevic, Armando Santoro, Bruno Daniele, Junji Furuse, Annette Jappe, Kevin Perraud, Oezlem Anak, Dalila B. Sellami, Li-Tzong Chen, Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. ,vol. 312, pp. 57- 67 ,(2014) , 10.1001/JAMA.2014.7189
Stijn van Laarhoven, Maria I. Fiel, Analisa Di Feo, Yujin Hoshida, Steven Yea, Sara Toffanin, Alex Ramos, John A. Martignetti, Vincenzo Mazzaferro, Jordi Bruix, Samuel Waxman, Myron Schwartz, Matthew Meyerson, Scott L. Friedman, Josep M. Llovet, Augusto Villanueva, Derek Y. Chiang, Pippa Newell, Judit Peix, Swan Thung, Clara Alsinet, Victoria Tovar, Sasan Roayaie, Beatriz Minguez, Manel Sole, Carlo Battiston, Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma Gastroenterology. ,vol. 135, pp. 1972- 1983 ,(2008) , 10.1053/J.GASTRO.2008.08.008
Peter R Galle, Alejandro Forner, Josep M Llovet, Vincenzo Mazzaferro, Fabio Piscaglia, Jean-Luc Raoul, Peter Schirmacher, Valérie Vilgrain, None, EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma Journal of Hepatology. ,vol. 69, pp. 182- 236 ,(2018) , 10.1016/J.JHEP.2018.03.019
Adrian M. Di Bisceglie, Tim F. Greten, Josep M. Llovet, Andrew Zhu, Jordi Bruix, Michel Ducreux, Eric Raymond, Vincenzo Mazzaferro, Jean Francois Dufour, Massimo Colombo, Tania Roskams, Riccardo Lencioni, EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer ,(2012)